Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myeloma

Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant

Bone Marrow Transplantation volume 33, pages 823–828 (2004)Cite this article

Summary:

To evaluate the role of high-dose melphalan and autologous transplant (AT) in reversing dialysis-dependent renal failure, 59 patients still on dialysis at the time of AT were analyzed. A total of 37 patients had been on dialysis ⩽6 months. A 5-year event-free and overall survival rate of all patients after AT was 24 and 36%, respectively. Of 54 patients evaluable for renal function improvement, 13 (24%) became dialysis independent at a median of 4 months after AT (range: 1–16). Dialysis duration ⩽6 months prior to first AT and pre-transplant creatinine clearance >10 ml/min were significant for renal function recovery: 12 of 36 (33%) ⩽6 months vs one of 18 patients (6%) >6 months on dialysis recovered renal function; 10 of 26 (38%) with >10 ml/min vs three of 28 (11%) with ⩽10 ml/min of creatinine clearance (both P<0.05). Quality of response after autotransplant was also significant: 12 of 31 (39%) being greater than partial remission after AT vs one of 21 patients (5%) attaining partial remission or less became independent of dialysis (P<0.05). Our data suggest that significant renal failure can be reversible and AT should be considered early in the disease course.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Knudsen LM, Hippe E, Hjorth M et al. Renal function in newly diagnosed multiple myeloma – a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol 1994; 53: 207–212.

    Article  CAS  PubMed  Google Scholar 

  2. Knudsen LM, Hjorth M, Hippe E . Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000; 65: 175–181.

    Article  CAS  PubMed  Google Scholar 

  3. Pichette V, Querin S, Desmeules M et al. Renal function recovery in end-stage renal disease. Am J Kidney Dis 1993; 22: 398–402.

    Article  CAS  PubMed  Google Scholar 

  4. Rota S, Mougenot B, Baudouin B et al. Multiple myeloma and severe renal failure: a clinicopathologic study of outcome and prognosis in 34 patients. Medicine 1987; 66: 126–137.

    Article  CAS  PubMed  Google Scholar 

  5. Komatsuda A, Wakui H, Ohtani H et al. Disappearance of nodular mesangial lesions in a patient with light chain nephropathy after long-term chemotherapy. Am J Kidney Dis 2000; 35: E9.

    Article  CAS  PubMed  Google Scholar 

  6. Pozzi C, Fogazzi GB, Banfi G et al. Renal disease and patient survival in light chain deposition disease. Clin Nephrol 1995; 43: 281–287.

    CAS  PubMed  Google Scholar 

  7. Comenzo RL, Vosburgh E, Falk RH et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998; 91: 3662–3670.

    CAS  PubMed  Google Scholar 

  8. Badros A, Barlogie B, Siegel E et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822–829.

    Article  CAS  PubMed  Google Scholar 

  9. National Cancer Institute: Cancer Therapy Evaluation Program: Common Toxicity Criteria, version 2, Bethesda, MD, National Cancer Institute, April 30, 1999.

  10. Gooley TA, Leisenring W, Crowley J, Storer BE . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695–706.

    Article  CAS  PubMed  Google Scholar 

  11. Hintze JL . Number Cruncher Statistical System 2001. NCSS Kaysville, UT.

  12. Kaplan EL, Meier P . Nonparametric estimation from incomplete observation. Journal of the American Statistical Association 1958; 53: 457–481.

    Article  Google Scholar 

  13. Collett D . Modeling Survival Data in Medical Research. Chapman & Hall: London, 1994.

    Book  Google Scholar 

  14. Lee CK, Barlogie B, Zangari ME et al. D.T.PACE, an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003; 21: 2732–2739.

    Article  CAS  PubMed  Google Scholar 

  15. Fassas AB, Spencer T, Desikan R et al. Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients. Br J Haematol 2002; 119: 164–168.

    Article  PubMed  Google Scholar 

  16. Barlogie B, McCoy J, Shaughnessy J et al. Total therapy II (TT II) for newly diagnosed multiple myeloma (MM): preliminary data on feasibility and efficacy in the first 231 enrolled patients; Comparison with Predecessor Trial Total Therapy I (TT I) (N=231). Blood 2001; 98: 683 (abstract 2857).

    Article  Google Scholar 

  17. Blade J, Fernandez-Llama P, Bosch F et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158: 1889–1893.

    Article  CAS  PubMed  Google Scholar 

  18. Torra R, Blade J, Cases A et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 1995; 91: 854–859.

    Article  CAS  PubMed  Google Scholar 

  19. Tricot G, Alberts DS, Johnson C et al. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res 1996; 2: 947–952.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, USA

    C-K Lee, M Zangari, B Barlogie, A Fassas, F van Rhee, R Thertulien, G Talamo, F Muwalla, E Anaissie, K Hollmig & G Tricot

Authors
  1. C-K Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Zangari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B Barlogie
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Fassas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F van Rhee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Thertulien
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G Talamo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F Muwalla
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. E Anaissie
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. K Hollmig
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. G Tricot
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C-K Lee.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, CK., Zangari, M., Barlogie, B. et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 33, 823–828 (2004). https://doi.org/10.1038/sj.bmt.1704440

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704440

Keywords

This article is cited by

Search

Advanced search

Quick links